Best Peptides for Immune Support — Evidence Review
"Immune support" is broad — it covers people seeking protection against infection, those with documented immune dysfunction, and those with autoimmune conditions where immune modulation (not…
"Immune support" is broad — it covers people seeking protection against infection, those with documented immune dysfunction, and those with autoimmune conditions where immune modulation (not enhancement) is the goal. The peptides with relevant data target different parts of the immune system.
Peptides with the strongest immune-modulating evidence
Thymosin Alpha-1
Naturally occurring peptide with characterized immune-modulating action. Increases regulatory T-cell function, modulates dendritic-cell activity, shifts cytokine balance.
Approved in some countries (not US) for chronic hepatitis B. Has Phase 3 trial data and post-marketing safety data. Sepsis trials have shown mortality benefit in some meta-analyses. Adjunctive use in oncology (during chemotherapy) is the largest off-label clinical context.
Full thymosin alpha-1 profile →
LL-37 (Cathelicidin)
Antimicrobial peptide with direct activity against bacteria, viruses, and fungi via membrane disruption — a mechanism resistant to bacterial-resistance evolution. Plays roles in both inflammation initiation and resolution. Therapeutic applications in immune support are still being characterized.
KPV (Lysine-Proline-Valine)
α-MSH fragment with anti-inflammatory action via melanocortin receptor signaling. More relevant to inflammatory regulation than direct immune enhancement. Phase 1/2 IBD trials emerging.
Supporting cast
Thymalin
Bovine thymus extract with immune-modulating properties. Russian-program clinical use. Less Western data than thymosin alpha-1.
What the evidence does not support
- "Immune boosting" in healthy adults to prevent ordinary infections (no peptide has shown this in controlled trials)
- BPC-157, TB-500, or tissue-repair peptides for immune function
- Use during active immunosuppressive therapy without coordinating with the prescribing team
- "Long COVID" peptide protocols without published efficacy data
Important interactions
If you are on biologic immunomodulating therapy (TNF inhibitors, IL-17 inhibitors, JAK inhibitors, B-cell depleters) for autoimmune disease, immune-modulating peptide use should be discussed with the prescriber before initiation. Compounding immune effects is the central concern.
For oncology patients on chemotherapy — thymosin alpha-1 has clinical context here, but use must be coordinated with the oncology team, not self-directed.
Practical considerations
For "immune support" in healthy adults, the strongest evidence base outside peptides:
- Vaccination against age-appropriate pathogens
- Adequate sleep (7–9 hours)
- Caloric balance and adequate protein
- Vitamin D adequacy (correct deficiency where present)
- Smoking cessation
- Stress management
These have stronger evidence than any peptide for general immune health.
Where to source
- Thymosin Alpha-1 vendor rankings — limited; lower independent testing volume
- LL-37 vendor rankings — limited
- KPV vendor rankings — limited
What we don't know
- Whether thymosin alpha-1 produces meaningful improvement in immune outcomes outside the contexts where it has clinical data (HBV, sepsis, oncology adjunct)
- Whether LL-37 will mature into a clinical antimicrobial
- Long-term safety of immune-modulating peptide therapy
- Optimal dosing for any immune-support use case in healthy adults
Methodology
Read the full methodology.
This page is educational. Immune-related concerns benefit from proper evaluation. Peptide therapy outside clinical contexts is not standard care for general immune health.